<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02080195</url>
  </required_header>
  <id_info>
    <org_study_id>J13134</org_study_id>
    <secondary_id>NA_00082453</secondary_id>
    <nct_id>NCT02080195</nct_id>
  </id_info>
  <brief_title>Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)</brief_title>
  <official_title>A Phase I/II Study of Nonmyeloablative Conditioning and Transplantation of Human Leukocyte Antigen (HLA)-Matched, Partially HLA-mismatched, HLA-haploidentical or Matched Unrelated Bone Marrow for Patients With Refractory SLE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maryland Stem Cell Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main goal of the study is to determine if bone marrow transplant (BMT) from a less
      specific pool of donors in combination with high dose cyclophosphamide can induce remission
      of refractory systemic lupus erythematosus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Systemic lupus erythematosus (SLE) is a devastating systemic autoimmune disease that
      predominantly affects young women, is more common in African-Americans than in whites, and
      results in poor quality of life. Lupus has no cure, and up to 90% of patients require
      corticosteroids for disease control. More than half of patients with lupus have permanent
      organ damage, much of which is either directly due to or increased by corticosteroids. To
      satisfactorily manage moderate-to-severe SLE, the investigators need effective treatments
      that will allow corticosteroid-sparing.

      High-dose chemotherapy followed by autologous BMT or peripheral blood progenitor
      transplantation (PBSCT) has been proposed as a novel approach to treat severe autoimmune
      diseases. Allogeneic BMT is not currently utilized for the routine treatment of SLE because
      of the significant morbidity (GVHD) and mortality associated with the procedure.

      The investigators have recently developed an approach to BMT using post-transplant
      cyclophosphamide that allows us to safely perform allogeneic BMT from matched, mismatched,
      unrelated or haploidentical donors. Transplant-related mortality, graft-failure and risk of
      GVHD have been very low with this approach. Furthermore, this approach allows us to greatly
      expand the donor pool since any patient shares exactly one HLA haplotype with each biological
      parent or child and half of siblings, an eligible haploidentical donor can be identified
      rapidly in nearly all cases.

      This trial will employ a fludarabine + cyclophosphamide conditioning along with
      posttransplantation cyclophosphamide on for patients with refractory SLE. The purpose of this
      trial is to improve the salvage rate for patients with refractory SLE through a reformatting
      of the immune system.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was unable to accrue subjects
  </why_stopped>
  <start_date type="Actual">September 13, 2016</start_date>
  <completion_date type="Actual">March 29, 2017</completion_date>
  <primary_completion_date type="Actual">March 28, 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Feasibility of the Conditioning Regimen and Post Transplantation Cyclophosphamide in Refractory SLE Patients With Donors Having Various Degrees of Matching</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants who were alive at 1 year after transplant and who had not suffered graft rejection, acute or chronic GVHD, or Grade 3 or higher (CTCAE V4.0) adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>RIFLE Score</measure>
    <time_frame>1 year</time_frame>
    <description>Change in Responder Index for Systemic Lupus Erythematosis (RIFLE) assessment. This is a qualitative assessment of organ function. The 12 month response will be assessed as:
complete= complete or partial resolution in more than one organ, partial= complete or partial resolution in at least one organ, the same= no change or no worsening in any organ, worse= worsening in any organ</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Number of patients alive and alive without relapse, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft Failure</measure>
    <time_frame>60 days</time_frame>
    <description>Number of participants with primary and/or secondary graft failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute Graft Versus Host Disease (GVHD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Percentage of participants who developed grades II-IV and grades III-IV acute GVHD. Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft Versus Host Disease (GVHD)</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Percentage of participants who developed chronic GVHD as defined by the NIH consensus criteria. This system gives scores from 0 to 3 for Karnofsky performance score, skin, mouth, eyes, gastrointestinal, liver, lungs, joints, and genitals, as well as an overall severity (mild, moderate, or severe).
Mild chronic GVHD involves only 1 or 2 organs or sites (except the lung), with no clinically significant functional impairment (maximum of score 1 in all affected organs or sites).
Moderate chronic GVHD involves 1) at least 1 organ or site with clinically significant but no major disability (maximum score of 2 in any affected organ or site) OR 2) 3 or more organs or sites with no clinically significant functional impairment (maximum score of 1 in all affected organs or sites).
Severe chronic GVHD indicates major disability caused by chronic GVHD (score of 3 in any organ or site).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Lupus Erythematosus</condition>
  <condition>Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nonmyeloablative conditioning with rabbit antithymocyte globulin, cyclophosphamide, fludarabine, and total body irradiation. Allogeneic bone marrow transplant on Day 0. Graft versus host disease (GVHD) prophylaxis with cyclophosphamide, mycophenolate mofetil, and tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>14.5 mg/kg/day on Days -6 and -5. 50 mg/kg/day on Days 3 and 4.</description>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
    <other_name>Cytoxan</other_name>
    <other_name>Cy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>30 mg/m^2/day on Days -6 through -2.</description>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Starting on Day 5. Dose will be adjusted according to blood levels.</description>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
    <other_name>FK-506</other_name>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>15 mg/kg three times per day from Day 5 to Day 35.</description>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabbit antithymocyte globulin</intervention_name>
    <description>0.5 mg/kg on Day -9. 2 mg/kg/day on Days -8 and -7.</description>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
    <other_name>Thymoglobulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>200 centigray on Day -1.</description>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allogeneic bone marrow transplant</intervention_name>
    <description>Infusion on Day 0.</description>
    <arm_group_label>Nonmyeloablative Conditioning and BMT</arm_group_label>
    <other_name>BMT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Four or more American College of Rheumatology (ACR) criteria for the classification of
             SLE or 4 or more of the SLICE criteria

          -  Involvement of one or more of the following organ systems: renal, neurologic,
             hematologic, cardiac, pulmonary, gastrointestinal

          -  A lack of response to corticosteroids in moderate-to-high doses, and to either an
             equivalent degree of immunosuppression with azathioprine, methotrexate, cyclosporin,
             tacrolimus, belimumab, rituximab, mycophenolate mofetil, and/or appropriate other
             treatment

          -  Patients should be eligible for transplantation according to the BMT Policy Manual

        Exclusion Criteria:

          -  Age less than 18 years and over 75 years

          -  Any risk of pregnancy

          -  Patients who are preterminal or moribund
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Javier Bolaños-Meade, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2014</study_first_posted>
  <results_first_submitted>September 6, 2018</results_first_submitted>
  <results_first_submitted_qc>September 6, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2018</results_first_posted>
  <last_update_submitted>September 19, 2019</last_update_submitted>
  <last_update_submitted_qc>September 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/95/NCT02080195/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Nonmyeloablative Conditioning and BMT</title>
          <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Nonmyeloablative Conditioning and BMT</title>
          <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Feasibility of the Conditioning Regimen and Post Transplantation Cyclophosphamide in Refractory SLE Patients With Donors Having Various Degrees of Matching</title>
        <description>Number of participants who were alive at 1 year after transplant and who had not suffered graft rejection, acute or chronic GVHD, or Grade 3 or higher (CTCAE V4.0) adverse events.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nonmyeloablative Conditioning and BMT</title>
            <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
          </group>
        </group_list>
        <measure>
          <title>The Feasibility of the Conditioning Regimen and Post Transplantation Cyclophosphamide in Refractory SLE Patients With Donors Having Various Degrees of Matching</title>
          <description>Number of participants who were alive at 1 year after transplant and who had not suffered graft rejection, acute or chronic GVHD, or Grade 3 or higher (CTCAE V4.0) adverse events.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>RIFLE Score</title>
        <description>Change in Responder Index for Systemic Lupus Erythematosis (RIFLE) assessment. This is a qualitative assessment of organ function. The 12 month response will be assessed as:
complete= complete or partial resolution in more than one organ, partial= complete or partial resolution in at least one organ, the same= no change or no worsening in any organ, worse= worsening in any organ</description>
        <time_frame>1 year</time_frame>
        <population>The only enrolled participant on this study was never assessed for a follow-up RIFLE scale, so no data was collected for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Nonmyeloablative Conditioning and BMT</title>
            <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
          </group>
        </group_list>
        <measure>
          <title>RIFLE Score</title>
          <description>Change in Responder Index for Systemic Lupus Erythematosis (RIFLE) assessment. This is a qualitative assessment of organ function. The 12 month response will be assessed as:
complete= complete or partial resolution in more than one organ, partial= complete or partial resolution in at least one organ, the same= no change or no worsening in any organ, worse= worsening in any organ</description>
          <population>The only enrolled participant on this study was never assessed for a follow-up RIFLE scale, so no data was collected for this outcome measure.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <description>Number of patients alive and alive without relapse, respectively.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nonmyeloablative Conditioning and BMT</title>
            <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <description>Number of patients alive and alive without relapse, respectively.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Event Free Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Graft Failure</title>
        <description>Number of participants with primary and/or secondary graft failure.</description>
        <time_frame>60 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nonmyeloablative Conditioning and BMT</title>
            <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
          </group>
        </group_list>
        <measure>
          <title>Graft Failure</title>
          <description>Number of participants with primary and/or secondary graft failure.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Primary graft failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Secondary graft failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute Graft Versus Host Disease (GVHD)</title>
        <description>Percentage of participants who developed grades II-IV and grades III-IV acute GVHD. Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nonmyeloablative Conditioning and BMT</title>
            <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
          </group>
        </group_list>
        <measure>
          <title>Acute Graft Versus Host Disease (GVHD)</title>
          <description>Percentage of participants who developed grades II-IV and grades III-IV acute GVHD. Acute GVHD is defined by the Przepiorka criteria, which stages the degree of organ involvement in the skin, liver, and gastrointestinal (GI) tract, based on severity, with Stage 1+ being least severe and stage 4+ being the most severe. Grading of acute GVHD is as follows: Grade I (skin involvement stages 1+ to 2+, with no liver or GI involvement), Grade II (skin involvement stages 1+ to 3+, liver 1+, GI tract 1+), Grade III (skin involvement stages 2+ to 3+, liver 1+, GI tract 2+ to 4+), Grade IV (skin involvement stages 4+, Liver 4+).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grades II-IV acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grades III-IV acute GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft Versus Host Disease (GVHD)</title>
        <description>Percentage of participants who developed chronic GVHD as defined by the NIH consensus criteria. This system gives scores from 0 to 3 for Karnofsky performance score, skin, mouth, eyes, gastrointestinal, liver, lungs, joints, and genitals, as well as an overall severity (mild, moderate, or severe).
Mild chronic GVHD involves only 1 or 2 organs or sites (except the lung), with no clinically significant functional impairment (maximum of score 1 in all affected organs or sites).
Moderate chronic GVHD involves 1) at least 1 organ or site with clinically significant but no major disability (maximum score of 2 in any affected organ or site) OR 2) 3 or more organs or sites with no clinically significant functional impairment (maximum score of 1 in all affected organs or sites).
Severe chronic GVHD indicates major disability caused by chronic GVHD (score of 3 in any organ or site).</description>
        <time_frame>Up to 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Nonmyeloablative Conditioning and BMT</title>
            <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft Versus Host Disease (GVHD)</title>
          <description>Percentage of participants who developed chronic GVHD as defined by the NIH consensus criteria. This system gives scores from 0 to 3 for Karnofsky performance score, skin, mouth, eyes, gastrointestinal, liver, lungs, joints, and genitals, as well as an overall severity (mild, moderate, or severe).
Mild chronic GVHD involves only 1 or 2 organs or sites (except the lung), with no clinically significant functional impairment (maximum of score 1 in all affected organs or sites).
Moderate chronic GVHD involves 1) at least 1 organ or site with clinically significant but no major disability (maximum score of 2 in any affected organ or site) OR 2) 3 or more organs or sites with no clinically significant functional impairment (maximum score of 1 in all affected organs or sites).
Severe chronic GVHD indicates major disability caused by chronic GVHD (score of 3 in any organ or site).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were assessed weekly through at least Day 60.</time_frame>
      <desc>Reportable serious adverse events per protocol include: any mortality within the first 100 days after bone marrow transplant (BMT), any graft failures (defined as &lt;5% donor chimerism) associated with failure of neutrophil recovery to &gt;500/mm³ by day ~60 after transplantation, and all unexpected events as deemed significant by the PIs. Other events were neither tracked nor reported for this study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Nonmyeloablative Conditioning and BMT</title>
          <description>Nonmyeloablative Conditioning and Bone Marrow Transplant in Systemic Lupus Erythematosus patients
Cyclophosphamide: Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
Sodium-2-mercapto ethane sulphonate: Antineoplastic detoxifying agent
Fludarabine monophosphate: Purine antimetabolite
Tacrolimus: Calcineurin inhibitor
Mofetil: Immunosuppressant
Rabbit antithymocyte globulin: Selective immunosuppressant</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Javier Bolaños Meade, MD</name_or_title>
      <organization>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</organization>
      <phone>410-614-6398</phone>
      <email>fbolano2@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

